Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase

Archives of Pharmacal Research

Volumn 37, Issue 9, 2014, Pages 1169-1176

  Choi, You Jin ^a   Suh, Hyo Ryung ^a   Yoon, Yujin ^a   Lee, Kyung Jin ^a   Kim, Dong Gwang ^a   Kim, Sanghee ^a   Lee, Byung Hoon ^a  

^a Seoul National University   (South Korea)

Author keywords

AMPK; High fat diet; NAFLD; Resveratrol derivatives

Indexed keywords

FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER PROTECTIVE AGENT; LUCIFERASE; MESSENGER RNA; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; RESVERATROL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; LIPOTROPIC AGENT; STILBENE DERIVATIVE; SY-102;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATTY LIVER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; LIPID STORAGE; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; RANDOMIZATION; RAT; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GERMFREE ANIMAL; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER CELL; METABOLISM; METHYLATION; NON-ALCOHOLIC FATTY LIVER DISEASE; PHOSPHORYLATION; PROTEIN PROCESSING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL LINE; CELL SURVIVAL; ENZYME ACTIVATION; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; LIPOTROPIC AGENTS; MALE; METHYLATION; MICE, INBRED ICR; NON-ALCOHOLIC FATTY LIVER DISEASE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RANDOM ALLOCATION; RATS; SPECIFIC PATHOGEN-FREE ORGANISMS; STILBENES;

EID: 84906934962     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-014-0347-z     Document Type: Article

References (28)

1. Ajmo, J.M., X. Liang, C.Q. Rogers, B. Pennock, and M. You. 2008. Resveratrol alleviates alcoholic fatty liver in mice. American Journal of Physiology. Gastrointestinal and Liver Physiology 295: 833-842.
2. Angulo, P. 2002. Nonalcoholic fatty liver disease. New England Journal of Medicine 346: 1221-1231.
3. Baur, J.A., and D.A. Sinclair. 2006. Therapeutic potential of resveratrol: The in vivo evidence. Nature Reviews Drug Discovery 5: 493-506. (Pubitemid 44136961)
4. Bellentani, S., G. Saccoccio, F. Masutti, L.S. Crocè, G. Brandi, F. Sasso, G. Cristanini, and C. Tiribelli. 2000. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Annals of Internal Medicine 132: 112-117. (Pubitemid 30044177)
5. Borra, M.T., B.C. Smith, and J.M. Denu. 2005. Mechanism of human SIRT1 activation by resveratrol. Journal of Biological Chemistry 280: 17187-17195. (Pubitemid 41389185)
6. Chun, Y.J., C. Lim, S.O. Ohk, J.M. Lee, J.H. Lee, S. Choi, and S. Kim. 2011. trans-Stilbenoids: Potent and selective inhibitors for human cytochrome P4501B1. Medicinal Chemistry Communications 2: 402-405.
7. Gómez-Lechón, M.J., M.T. Donato, A. Martínez-Romero, N. Jiménez, J.V. Castell, and J.E. O'Connor. 2007. A human hepatocellular in vitro model to investigate steatosis. Chemico-Biological Interactions 165: 106-116. (Pubitemid 46072796)
8. Hou, X., S. Xu, K.A. Maitland-Toolan, K. Sato, B. Jiang, Y. Ido, F. Lan, K. Walsh, M. Wierzbicki, T.J. Verbeuren, R.A. Cohen, and M. Zang. 2008. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. Journal of Biological Chemistry 283: 20015-20026.
9. Hwahng, S.H., S.H. Ki, E.J. Bae, H.E. Kim, and S.G. Kim. 2009. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 49: 1913-1925.
10. Kraegen, E.W., P.W. Clark, A.B. Jenkins, E.A. Daley, D.J. Chisholm, and L.H. Storlien. 1991. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40: 1397-1403.
11. Khanal, T., J.H. Choi, Y.P. Hwang, Y.C. Chung, and H.G. Jeong. 2009. Protective effects of saponins from the root of Platycodon grandiflorum against fatty liver in chronic ethanol feeding via the activation of AMP-dependent protein kinase. Food and Chemical Toxicology 47: 2749-2754.
12. Lee, M.S., D. Kim, K. Jo, and J.K. Hwang. 2010. Nordihydroguaiaretic acid protects against high-fat diet-induced fatty liver by activating AMP-activated protein kinase in obese mice. Biochemical and Biophysical Research Communications 401: 92-97.
13. Li, S., M.S. Brown, and J.L. Goldstein. 2010. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proceedings of the National Academy of Sciences of the United States of America 107: 3441-3446.
14. Li, Y., S. Xu, M.M. Mihaylova, B. Zheng, X. Hou, B. Jiang, O. Park, Z. Luo, E. Lefai, J.Y. Shyy, B. Gao, M. Wierzbicki, T.J. Verbeuren, R.J. Shaw, R.A. Cohen, and M. Zang. 2011. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metabolism 13: 376-388.
15. Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25: 402-408. (Pubitemid 34164012)
16. Manna, S.K., A. Mukhopadhyay, and B.B. Aggarwal. 2000. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. The Journal of Immunology 164: 6509-6519. (Pubitemid 30408836)
17. McMillian, M.K., E.R. Grant, Z. Zhong, J.B. Parker, L. Li, R.A. Zivin, M.E. Burczynski, and M.D. Johnson. 2001. Nile red binding to HepG2 cells: An improved assay for in vitro studies of hepatosteatosis. In Vitro and Molecular Toxicology 14: 177-190. (Pubitemid 34326670)
18. Olas, B., B. Wachowicz, J. Saluk-Juszczak, and T. Zieliński. 2002. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thrombosis Research 107: 141-145. (Pubitemid 35341502)
19. Rossmeisl, M., J.S. Rim, R.A. Koza, and L.P. Kozak. 2003. Variation in type 2 diabetes-related traits in mouse strains susceptible to diet-induced obesity. Diabetes 52: 1958-1966. (Pubitemid 36919787)
20. Samuel, V.T., Z.X. Liu, X. Qu, B.D. Elder, S. Bilz, D. Befroy, A.J. Romanelli, and G.I. Shulman. 2004. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. Journal of Biological Chemistry 279: 32345-32353. (Pubitemid 39014687)
21. Schultz, J.R., H. Tu, A. Luk, J.J. Repa, J.C. Medina, L. Li, S. Schwendner, S. Wang, M. Thoolen, D.J. Mangelsdorf, K.D. Lustig, and B. Shan. 2000. Role of LXRs in control of lipogenesis. Genes and Development 14: 2831-2838.
22. Shang, J., L.L. Chen, F.X. Xiao, H. Sun, H.C. Ding, and H. Xiao. 2008. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacologica Sinica 29: 698-706. (Pubitemid 351799479)
23. Wang, G.L., Y.C. Fu, W.C. Xu, Y.Q. Feng, S.R. Fang, and X.H. Zhou. 2009. Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochemical and Biophysical Research Communications 380: 644-649.
24. Yahagi, N., H. Shimano, A.H. Hasty, T. Matsuzaka, T. Ide, T. Yoshikawa, M. Amemiya-Kudo, S. Tomita, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, J. Osuga, K. Harada, T. Gotoda, R. Nagai, S. Ishibashi, and N. Yamada. 2002. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. Journal of Biological Chemistry 277: 19353-19357. (Pubitemid 34967441)
25. Yoshikawa, T., H. Shimano, M. Amemiya-Kudo, N. Yahagi, A.H. Hasty, T. Matsuzaka, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, J. Osuga, K. Harada, T. Gotoda, S. Kimura, S. Ishibashi, and N. Yamada. 2001. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Molecular and Cellular Biology 21: 2991-3000. (Pubitemid 32298367)
26. You, M., M. Fischer, M.A. Deeg, and D.W. Crabb. 2002. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). Journal of Biological Chemistry 277: 29342-29347.
27. Zang, M.W., S.Q. Xu, K.A. Maitland-Toolan, A. Zuccollo, X.Y. Hou, B.B. Jiang, M. Wierzbicki, T.J. Verbeuren, and R.A. Cohen. 2006. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55: 2180-2191. (Pubitemid 44743614)
28. Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M.F. Hirshman, L.J. Goodyear, and D.E. Moller. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. Journal of Clinical Investigation 108: 1167-1174. (Pubitemid 32995375)